We have synthetized two compounds —pyridinolcarbamate and phthalazinol— which are commonly active in preventing the edematous arterial reaction of rabbit aorta, and in antagonizing the vasocontracting and platelet-aggregating effect of thromboxane A
2. They have no vasodilative effect in therapeutic doses. The potency of phthalazinol in roughly 10 times greater than that of pyridinolcarbamate. Thromboxane A
2, besides its highly potent vasocontracting and platelet aggregating effect, has been known to inhibit the release of lipid from adipocytes. This profoundly lowers cyclic AMP of adipocytes by inhibiting the activity of adenyl cyclase.
Such evidence shows the importance of research to see whether the two above-mentioned thromboxane A
2 antagonistic substances exert any anti-atherosclerotic effect in man and animals.
(1) Experimental evidence
In the experiments with rabbits, the anti-atherosclerotic effect of pyridinolcarbamate has already been reported. In this paper the anti-atherosclerotic effect induced by the daily administration of phthalazinol (20mg/day, p. o.) on atherosclerotic rabbits, produced by cholesterol-feeding (1% cholesterol pellets for 15 weeks), was introduced. The treatment was performed under a cholesterol-free diet. The 15 weeks and 30 weeks regimes were compared.
The elimination of cholesterol from the aorta was definitely accelerated by phthalazinol as compared with placebo. It became statistically significant in the 30 weeks regimen. The histochemical analysis revealed a significantly faster removal of stainable lipid (by Oil red-O) from atheromatous lesions of the treated group, compared with the placebo group. And it became much more pronounced in the 30 weeks regimen than the 15 weeks regimen, including the differences in the other histochemical parameters, showing a definite enhancement by phthalazinol in regression of atheromatous lesions.
The cerebral thrombosis of rats (Furlow and Bass, 1974), cerebral hemorrhage of stroke strains of spontaneously hypertensive rats, kept on 1% salt water for 5 weeks, cerebral hemorrhage of spontaneously hypertensive rats induced immediately by intracarotid injection of thromboxane A
2 mixture (Shimamoto et al 1976), and experimental cerebral infarction induced by an intracarotid injection of thromboxane A
2 mixture in rabbits and experimental myocardial infarction induced by its intra-coronary injection in rabbits respectively, were significantly prevented by phthalazinol in a dose of 0.1-1.0mg/kg given intravenously. Such preventive effects were considered to come mainly from the thromboxane A
2-antagonistic effect of phthalazinol, if not all.
(2) Clinical evidence
In order to confirm an anti-atherosclerotic effect of a drug (1) an angiological improvement of the plaque, (2) an increase in the nutritional tissue flow of ischemic lesions, and (3) an improvement in prognosis are required.
In clinical applications of pyridinolcarbamate, a double blind trial of 2 years regimen with pyridinolcarbamate (2g/day) and placebo has been performed by Terry et al (1975). They evaluated their data in 38 patients suffering from advanced atherosclerosis of the lower extremities by an angiographical technique. They showed a statistically significant preventive effect on progression of angiological changes of the arteries of their lower leg by pyridinolcarbamate (P<0.001).
The atherosclerotic gangrene of 135 cases was challenged by inositol niacinate (1.2g daily) and by pyridinolcarbamate (1.5g daily) by Mishima et al under the double blind trial. They showed a favorable response with pyridinolcarbamate, significantly more effective than the vasodilator (P=0.0006).
The preventive effect of pyridinolcarbamate on apoplectic attacks, among postapoplectic patients, has been shown by Kato, Goto et al by their well-controlled 4 year observation. A significant improvement in prog
抄録全体を表示